Therapeutic restoration of miR‐19a‐3p or blockade of TGF‐β reinforced the CD4+ T cell anti‐tumour activity and restrained the progression of HBx‐overexpressing DLBCL in vivo. The gene discussed is CD4; the disease is neoplasm.